Why Is Ionis Pharmaceuticals (IONS) Stock Down -23.54% Today?
Key Takeaways
- IONS shares plunged approximately 23.54% on Thursday, closing at $64.58 after the previous session's close of $84.46.
- The primary catalyst was the failure of the Phase 3 CARDIO-TTRansform trial of eplontersen to meet its primary efficacy endpoint in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
- The trial, conducted in partnership with AZN, did not demonstrate a statistically significant reduction in cardiovascular mortality and recurrent cardiovascular events versus placebo through Week 140.
- The setback effectively removes a major near-term growth catalyst from Ionis's pipeline and reshapes the competitive landscape in the ATTR-CM market, benefiting rivals such as ALNY.
- Trading volume surged well above the three-month daily average, reflecting intense institutional and retail repositioning.
- Investors are now focused on the full data presentation at the European Society of Cardiology Congress in August 2026 and potential analyst downgrades.
Opening Summary
IONS, Ionis Pharmaceuticals, Inc., a pioneer in RNA-targeted therapeutics with a diversified pipeline spanning neurology, cardiometabolic disease, and gene editing, suffered one of its steepest single-session declines in over five years on Thursday. Shares closed at $64.58, down 23.54% from the prior session's close of $84.46, after the company and its partner AstraZeneca (AZN) announced that the highly anticipated Phase 3 CARDIO-TTRansform study of eplontersen failed to meet its primary efficacy endpoint. The selloff erased months of accumulated gains and pulled the stock sharply below its 52-week high of $86.74, which had been touched earlier in the same session.
Phase 3 CARDIO-TTRansform Trial Misses Primary Endpoint
The overwhelming driver behind Thursday's collapse was the top-line readout from the CARDIO-TTRansform study, a global, randomized, double-blind, placebo-controlled Phase 3 trial evaluating eplontersen in adults with ATTR-CM. The trial enrolled 1,432 participants across 130 sites in 20 countries, making it the largest ATTR-CM study ever conducted. The primary endpoint — a composite of cardiovascular mortality and recurrent cardiovascular clinical events through Week 140 — was not met. In a contemporary patient population receiving standard of care, including a majority on stabilizer therapy, adding eplontersen did not provide a statistically significant benefit compared with placebo.
At baseline, 57% of participants in both treatment arms were already receiving stabilizer therapy, and an additional 24% in each arm initiated a stabilizer during the trial. A prespecified subgroup analysis did show a nominally significant hazard ratio of 0.71 for the composite endpoint in patients receiving eplontersen monotherapy versus placebo. However, no treatment effect was observed among patients on stabilizer therapy at baseline. While several secondary, imaging, and biomarker endpoints favored eplontersen, and the drug's safety profile remained consistent with prior studies, the headline failure on the primary endpoint was the decisive factor for the market.
A Major Pipeline Catalyst Evaporates
The CARDIO-TTRansform readout had been positioned by Ionis management as a cornerstone of the company's 2026 growth narrative. Eplontersen, marketed as WAINUA, is already approved in more than 20 countries for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN). However, the ATTR-CM indication represented a far larger commercial opportunity — estimated at five to ten times the size of the polyneuropathy market — with peak sales projections that had reached into the billions of dollars contingent on a positive trial outcome. The failure to meet the primary endpoint now casts serious doubt on eplontersen's ability to compete in the broader and more commercially lucrative ATTR-CM market, narrowing the drug's revenue trajectory substantially.
Ionis CEO Brett Monia acknowledged the disappointment, stating that the results "reflect the rapidly evolving treatment landscape, in which contemporary ATTR-CM patients are widely treated with stabilizers," while emphasizing that the company remains "well positioned to create substantial value" through its wholly owned portfolio, including the ongoing launch of TRYNGOLZA and a robust pipeline of wholly owned medicines.
Competitive Landscape Shifts in ATTR-CM
The trial failure has immediate implications for the competitive dynamics in the ATTR-CM space. Alnylam Pharmaceuticals (ALNY) already holds an approved ATTR-CM indication for its RNAi therapy Amvuttra (vutrisiran), which has been gaining commercial momentum since its label expansion. Pfizer's (PFE) tafamidis (Vyndaqel/Vyndamax) remains well-established as the standard-of-care stabilizer in the indication, and BridgeBio's (BBIO) acoramidis received FDA approval in November 2024. With eplontersen now falling short, the near-term competitive threat to these established and emerging players is significantly diminished, a dynamic that was reflected in relative strength among ATTR-CM competitors during Thursday's session.
Market Context and Trading Activity
The selloff in IONS was entirely company-specific, with broader equity indices showing mixed but relatively muted performance. The S&P 500 edged slightly lower, the Dow Jones Industrial Average declined, and the Nasdaq Composite posted a modest gain — underscoring that the move was driven by the trial news rather than any macroeconomic or sector-wide pressure. Trading volume in IONS surged dramatically, with shares changing hands at multiples of the three-month average daily volume of approximately 1.86 million, indicating heavy institutional repositioning and active retail participation.
From a technical perspective, the stock had failed to breach the $86.74 resistance level in the prior session — a level that had also capped upside moves in February 2026 and as far back as April 2017. Thursday's plunge sent shares through multiple support levels, with the stock trading at levels not seen in seven months. The magnitude of the decline marked the largest single-day percentage drop for IONS since March 2021.
Trending AI Robots
In volatile market environments like the one impacting IONS today, traders increasingly turn to algorithmic strategies to navigate sharp price swings and identify opportunities across thousands of tickers. Tickeron offers hundreds of AI-powered trading bots, each designed with distinct strategies, timeframes, and performance metrics tailored to different market conditions. Only the strongest-performing bots under current market dynamics are featured in the curated Trending AI Robots section, providing traders with a streamlined way to discover strategies that have demonstrated real-time effectiveness. Whether markets are driven by clinical trial outcomes, earnings surprises, or macroeconomic shifts, these AI bots continuously adapt, offering a data-driven complement to traditional analysis. Explore the Trending AI Robots page to see which strategies are currently leading the pack.
What Comes Next for IONS
The immediate focus for investors shifts to the full data presentation from the CARDIO-TTRansform trial, scheduled for the European Society of Cardiology Congress in August 2026. Detailed secondary endpoint analyses, biomarker data, and subgroup findings will be scrutinized for any signals that could support a narrower regulatory path or inform future development strategies for eplontersen in ATTR-CM. Additionally, market participants will closely monitor analyst revisions in the coming days. Prior to the trial readout, Wall Street consensus on IONS was overwhelmingly bullish, with an average price target well above current levels. A wave of downgrades and target reductions is widely anticipated.
Beyond eplontersen, attention will return to Ionis's wholly owned pipeline. The company has multiple independent launches underway, including TRYNGOLZA, and continues to advance a pipeline of potentially transformational medicines across neurology and cardiometabolic disease. Management reiterated its commitment to achieving cash flow breakeven by 2028. However, the loss of the ATTR-CM catalyst raises the stakes for execution across the remainder of the portfolio, and any additional pipeline setbacks would likely amplify investor concerns about the company's growth trajectory.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
IONS's RSI Oscillator ascends from oversold territory
The RSI Oscillator for IONS moved out of oversold territory on August 03, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 26 similar instances when the indicator left oversold territory. In of the 26 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 07, 2026. You may want to consider a long position or call options on IONS as a result. In of 102 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for IONS just turned positive on August 03, 2026. Looking at past instances where IONS's MACD turned positive, the stock continued to rise in of 52 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IONS advanced for three days, in of 277 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 212 cases where IONS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IONS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
IONS broke above its upper Bollinger Band on August 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. IONS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock slightly better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (22.573) is normal, around the industry mean (20.145). P/E Ratio (0.000) is within average values for comparable stocks, (22.992). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.861). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (11.148) is also within normal values, averaging (444.692).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of antisense drugs
Industry Biotechnology
Advertisement